Axiom (Biotechnology) key facts
as of Oct 2026- Developer of a biotechnology platform designed to help scientists predict and mitigate drug toxicity earlier in the development process.
- Axiom (Biotechnology) is valued at approximately $121.0M as of Oct 2026 (last reported valuation).
- It has raised $30.0M; the latest was Early Stage VC ($15.0M) in Apr 2025.
- Notable investors include Abstract Ventures, CRV, Jeff Dean, Amplify Partners, Dimension (United States) — 14 tracked in total.
- Status: Privately Held (backing).
Axiom (Biotechnology)'s last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Axiom (Biotechnology): the Monday email on marks, rounds and moves
Axiom (Biotechnology) funding rounds
No funding rounds for Axiom (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Axiom (Biotechnology)
14+Membership and data by Private Market View
Axiom (Biotechnology) valuation
Axiom (Biotechnology)'s last reported valuation was $121 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Axiom (Biotechnology) investors
14 investors are on record for Axiom (Biotechnology), including Abstract Ventures, CRV, Jeff Dean and Amplify Partners. By type, the record holds 4 venture capital firms, 1 family office and 1 angel investor.
About Axiom (Biotechnology)
Developer of a biotechnology platform designed to help scientists predict and mitigate drug toxicity earlier in the development process. The company offers AI models trained on primary human liver biology, enabling pharmaceutical researchers to identify liver injury risks with greater accuracy, reduced cost, and without the use of animal testing.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Employees
- 25
- Website
- axi.om/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.